Pharmaceutical Composition for Treatment of Bone-Related Disease

Abstract

The present invention relates to a pharmaceutical composition for preventing or treating a bone-related disease; and the pharmaceutical composition is very effective in preventing or treating bone-related diseases in that it not only promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated. In addition, the present invention relates to a pharmaceutical composition for preventing or treating a menopausal disease, in particular, a menopausal bone disease; and the pharmaceutical composition is very effective in preventing or treating a menopausal bone-related disease in that it not only increases the volume of trabecular bone and promotes differentiation of preosteoblast cells into osteoblasts to induce production of mineralized nodules, but also, at the same time, inhibits differentiation of bone marrow cells into osteoclasts and the function of osteoclasts so that bone homeostasis is effectively regulated.

1 - 42 . (canceled) 
     
     
         43 . A method for preventing or treating a bone-related disease, comprising administering to a subject a composition comprising a sterol sulphate. 
     
     
         44 . The method according to  claim 43 , wherein the sterol is at least one selected from the group consisting of campesterol, sitosterol, stigmasterol, and cholesterol. 
     
     
         45 . The method according to  claim 44 , wherein the sterol sulphate is represented by Formula 1: 
       
         
           
           
               
               
           
         
       
     
     
         46 . The method according to  claim 44 , wherein the composition promotes differentiation of preosteoblast cells into osteoblasts. 
     
     
         47 . The method according to  claim 44 , wherein the composition inhibits differentiation of bone marrow cells into osteoclasts. 
     
     
         48 . The method according to  claim 44 , wherein the bone-related disease is at least one selected from the group consisting of osteoporosis, osteomalacia, osteopenia, bone atrophy, fibrous dysplasia, Paget's disease, hypercalcemia, neoplastic destruction of bone, cancer-related bone resorption diseases, fracture, osteolysis, osteoarthritis, and rheumatoid arthritis. 
     
     
         49 . The method according to  claim 48 , wherein the osteoporosis is at least one selected from the group consisting of primary osteoporosis due to aging, primary osteoporosis due to menopause, primary osteoporosis due to ovarian extraction, and primary osteoporosis due to testicular removal. 
     
     
         50 . The method according to  claim 48 , wherein the osteoporosis is at least one selected from the group consisting of glucocorticoid-induced osteoporosis, osteoporosis associated with hyperthyroidism, fixation-induced osteoporosis, heparin-induced osteoporosis, immunosuppression-induced osteoporosis, osteoporosis due to renal insufficiency, inflammatory osteoporosis, osteoporosis due to Cushing's syndrome, rheumatic osteoporosis, and osteoporosis due to estrogen synthesis inhibitor. 
     
     
         51 . The method according to  claim 44 , wherein the sterol sulphate is contained at a concentration of 1 μM to 1 mM.